Celcuity (FRA:7VR) Beginning Cash Position: €143.33 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7VR Celcuity Inc FRA:7VR
19 GF Score
Price €93.50
! 2 Warning Signs
View Full Analysis

What is Celcuity Beginning Cash Position?

Celcuity FRA:7VR +10.00% 19 Beginning Cash Position is €143.33 Mil as of Mar. 2026. GuruFocus rates FRA:7VR with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Celcuity's Beginning Cash Position for the quarter that ended in Mar. 2026 was €143.33 Mil.

Celcuity's quarterly Beginning Cash Position increased from Sep. 2025 (€39.49 Mil) to Dec. 2025 (€63.41 Mil) and increased from Dec. 2025 (€63.41 Mil) to Mar. 2026 (€143.33 Mil).

Celcuity's annual Beginning Cash Position increased from Dec. 2023 (€22.53 Mil) to Dec. 2024 (€29.28 Mil) but then declined from Dec. 2024 (€29.28 Mil) to Dec. 2025 (€19.23 Mil).

Celcuity Beginning Cash Position Related Terms

Celcuity Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Celcuity's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celcuity Beginning Cash Position Chart

Celcuity Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.30 79.57 22.53 29.28 19.23

Celcuity Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.83 14.29 39.49 63.41 143.33
FRA:7VR
19GF Score
Celcuity Inc FRA:7VR
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celcuity Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €143.33 Mil mean?
Celcuity (FRA:7VR) has a Beginning Cash Position of €143.33 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Celcuity and its competitors.
Is Celcuity's Beginning Cash Position too high?
Celcuity's current Beginning Cash Position is €143.33 Mil. Overall, Celcuity has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Celcuity's Beginning Cash Position compare to ERAS and TNGX?
Celcuity's Beginning Cash Position of €143.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Celcuity and its competitors. Celcuity's current Beginning Cash Position is €143.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celcuity stock overvalued right now?
Celcuity (FRA:7VR) has a current Beginning Cash Position of €143.33 Mil. The current Beginning Cash Position is €143.33 Mil. Celcuity's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Celcuity (FRA:7VR), the current Beginning Cash Position is €143.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celcuity Business Description

Other Exchanges CELC:USA
Address 16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
19GF Score

Get the complete analysis for FRA:7VR

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€93.50
Price